MwanzoAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
Bei iliyotangulia
$ 5.66
Bei za siku
$ 5.35 - $ 5.80
Bei za mwaka
$ 1.58 - $ 19.95
Thamani ya kampuni katika soko
347.84M USD
Wastani wa hisa zilizouzwa
1.82M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 416.00 | -99.59% |
Matumizi ya uendeshaji wa biashara | 17.83M | -63.41% |
Mapato halisi | -72.70M | -447.98% |
Kiwango cha faida halisi | elfu -17.48 | -85,981.67% |
Mapato kwa kila hisa | -1.07 | -456.67% |
EBITDA | -75.44M | -496.59% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 234.40M | -33.98% |
Jumla ya mali | 250.71M | -46.27% |
Jumla ya dhima | 54.51M | 13.13% |
Jumla ya hisa | 196.20M | — |
hisa zilizosalia | 68.55M | — |
Uwiano wa bei na thamani | 1.98 | — |
Faida inayotokana na mali | -64.90% | — |
Faida inayotokana mtaji | -81.67% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -72.70M | -447.98% |
Pesa kutokana na shughuli | -41.57M | -704.22% |
Pesa kutokana na uwekezaji | 38.82M | 135.91% |
Pesa kutokana na ufadhili | elfu 80.00 | -91.00% |
Mabadiliko halisi ya pesa taslimu | -2.44M | 97.83% |
Mtiririko huru wa pesa | -86.18M | -1,426.30% |
Kuhusu
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Ilianzishwa
2013
Tovuti
Wafanyakazi
384
